Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Basal Cell 2Basal Cell Nevus Syndrome 2Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Keratosis, Actinic 1

Interventions

pembrolizumab 40Nivolumab 18trametinib 13Cyclophosphamide 13dabrafenib 11Vemurafenib 10Interleukin-2 10Ipilimumab 9fludarabine 7Docetaxel 7fludarabine phosphate 6cemiplimab 6Paclitaxel 6Cisplatin 6Carboplatin 6atezolizumab 5Radiotherapy 5Drug Therapy 5Dacarbazine 5Blood Specimen Collection 5Biopsy 5poly ICLC 4binimetinib 4Therapeutics 4Psychiatric Rehabilitation 4sotigalimab 3montanide ISA 51 3encorafenib 3cobimetinib 3budigalimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × tazarotene × Dermatologic × Clear all
NCT00489086 2020-10-29

Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face

UCSF Benioff Children's Hospital Oakland

Phase 2 Completed
36 enrolled 7 charts
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡